

University of Groningen

Multi-drug resistant tuberculosis in the Netherlands

van Altena, Richard

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2016

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

van Altena, R. (2016). *Multi-drug resistant tuberculosis in the Netherlands: Personalised treatment and outcome*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Multi-Drug Tuberculosis in the Netherlands

Personalised treatment and outcome

Richard van Altena

Publication of this thesis was financially supported by

Afdeling Longziekten en Tuberculose UMCG
KNCV Tuberculosis Foundation
Stichting Beatrixoord Noord-Nederland
UMCG Centrum voor Revalidatie
UMCG Graduate School of Medical Sciences
VvAwT (Association of physicians working in tuberculosis control)

Cover C(Kees).J.P. Thijn, symbolisch-surrealistisch schilde – www.thijnhof.nl
Layout Ridderprint BV, the Netherlands – www.ridderprint.nl
Printed by Ridderprint BV, the Netherlands – www.ridderprint.nl
ISBN 978-94-6299-433-1
ISBN 978-94-6299-434-8 (electronic version)

© Richard van Altena 2016

Copyright of the published articles is with the corresponding journal or otherwise with the author. No part of this publication may be produced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing from the author or the copyright-owning journal.



rijksuniversiteit
 groningen

Multi-Drug Tuberculosis in the Netherlands Personalised treatment and outcome

Proefschrift

Ter verkrijging van de graad van doctor aan de
Rijksuniversiteit Groningen
op gezag van de
rector magnificus prof. dr. E. Sterken
en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op
dinsdag 15 november 2016 om 11:00 uur

door

Richard van Altena

geboren op 17 december 1947
te Haarlem

Promotores

Prof. dr. T.S. van der Werf

Prof. dr. H.A.M. Kerstjens

Copromotor

Dr. J.W.C. Alffenaar

Beoordelingscommissie

Prof. dr. G.B. Migliori

Prof. dr. F.G.J. Cobelens

Prof. dr. B.N.M. Sinha

Contents

1	Introduction	7
2	Immunology	17
a	Immunology in tuberculosis: challenges in monitoring of disease activity and identifying correlates of protection.	18
3	Individualised MDR-TB treatment	43
a	Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands.	44
b	Antituberculosis-drug resistance	56
c	Multidrug resistant tuberculosis	58
d	Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000-2009	60
e	Shorter treatment for multi-drug resistant tuberculosis: the good, the bad and the ugly	74
4	Aminoglycosides	79
a	Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis.	80
b	Reduced chance of hearing loss associated with Therapeutic Drug Monitoring of Aminoglycosides in the treatment of Multidrug Resistant Tuberculosis.	92
c	Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis.	110
5	Ertapenem	125
a	Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis.	126
b	Pharmacokinetic Modeling and Limited Sampling Strategies based on healthy volunteers for Monitoring of Ertapenem in MDR-TB patients.	137
6	Discussion & Future Perspectives	153
7	Appendices	
	Nederlandse samenvatting	173
	Lijst met afkortingen / list with abbreviations	189
	Dankwoord	191
	Curriculum vitae	201
	List of publications	205

